Non-Small Cell Lung Cancer Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers

Non-Small Cell Lung Cancer emerging therapies such as TransCon hGH, HyTropin (GX-H9), Somatrogon, and others are expected to boost the Non-Small Cell Lung Cancer Market in the upcoming years.

DelveInsight has launched a new report on "Non-Small Cell Lung Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent advancements in the Non-Small Cell Lung Cancer Treatment Market:
In January 2025, the U.S. Food and Drug Administration (FDA) granted priority review to Dizal's New Drug Application (NDA) for Sunvozertinib, a treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
In December 2024, Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company dedicated to addressing unmet oncology needs, announced that the FDA accepted its NDA for taletrectinib. This next-generation ROS1 tyrosine kinase inhibitor (TKI) is being evaluated for the treatment of advanced ROS1-positive NSCLC, regardless of prior treatment history.
In December 2024, Merus N.V. reported that the FDA approved BIZENGRI® (zenocutuzumab-zbco), the first and only therapy for adults with advanced unresectable or metastatic pancreatic adenocarcinoma or NSCLC harboring a neuregulin 1 (NRG1) gene fusion. This treatment is intended for patients who have experienced disease progression following prior systemic therapy.

Some of the key facts of the Non-Small Cell Lung Cancer Market Report:

The Non-Small Cell Lung Cancer (NSCLC) market in the 7MM is projected to reach approximately USD 30 billion in 2024 and is expected to grow at a significant CAGR throughout the forecast period (2020-2034).
NSCLC is more prevalent among individuals aged 65 and older compared to those under 65. In 2024, approximately 140,000 NSCLC cases were reported in the U.S. within this age group.
Additionally, in 2024, the total number of incident cases of NTRK1/2/3 gene fusion NSCLC in the U.S. was around 450.
Key players in the NSCLC market, including Novartis, AstraZeneca, Roche, Merck, Bristol Myers Squibb, and others, are driving advancements in innovative therapies and treatments.
Over the past decade, the NSCLC market has undergone a major transformation due to rising incidence rates, sustained adoption of approved therapies-particularly immune checkpoint inhibitors-the anticipated introduction of high-priced emerging treatments, and increasing awareness of key mutations such as KRAS, BRAF, and c-Met.
The treatment landscape has notably shifted from conventional systemic therapies to targeted and immunotherapies, which now represent the dominant approach.
NSCLC is progressively evolving into a biomarker-driven market. Among these, EGFR is one of the most lucrative segments, with blockbuster drugs like TAGRISSO leading the space, generating nearly USD 6 billion annually. Since TAGRISSO was approved for first-line use, the prevalence of patients with resistance mutations has increased, creating a significant unmet need in the post-TAGRISSO setting.
Currently, ALECENSA and ALUNBRIG are the preferred first-line ALK TKIs, with ALECENSA being the more widely used and dominating the ALK market. Before their introduction, XALKORI was the primary first-line treatment for ALK-positive patients.
According to DelveInsight's analysis, the total number of NSCLC incident cases in the 7MM was approximately 204,800 in 2024, with projections indicating further growth by 2034.
Key Non-Small Cell Lung Cancer companies such as AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, and others are evaluating new drugs for Non-Small Cell Lung Cancer to improve the treatment landscape.
Promising Non-Small Cell Lung Cancer therapies include KEYTRUDA (pembrolizumab), TECENTRIQ (atezolizumab), Telisotuzumab vedotin, Datopotamab deruxtecan (Dato-DXd), and others.
Key benefits of the Non-Small Cell Lung Cancer market report:
Non-Small Cell Lung Cancer market report covers a descriptive overview and comprehensive insight of the Non-Small Cell Lung Cancer Epidemiology and Non-Small Cell Lung Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Non-Small Cell Lung Cancer market report provides insights on the current and emerging therapies.
Non-Small Cell Lung Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Non-Small Cell Lung Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Non-Small Cell Lung Cancer market.

Got queries? Click here to know more about the Non-Small Cell Lung Cancer Market Landscape.

Non-Small Cell Lung Cancer Overview

Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, comprising 81% of all diagnosed cases. Early detection significantly improves prognosis; however, diagnosing NSCLC can be challenging. Its symptoms are often mistaken for common illnesses or attributed to the long-term effects of smoking. As a result, 80% of NSCLC cases are identified at advanced stages, making treatment more difficult.

When lung cancer is suspected, physicians typically recommend imaging tests such as CT, PET, or MRI scans to detect abnormalities in and around the lungs. Additionally, a sample of mucus may be examined under a microscope for further evaluation.

If initial tests suggest cancer, a lung biopsy may be performed. In some cases, a bronchoscopy is used to visually inspect the lungs and collect tissue samples. Once lung cancer is confirmed, genetic testing of the tissue can provide insights into the cancer's characteristics, helping to guide treatment decisions.

Non-Small Cell Lung Cancer Marketed Drugs
KEYTRUDA (pembrolizumab): Merck
TECENTRIQ (atezolizumab): Genentech/Roche

Non-Small Cell Lung Cancer Emerging Drugs
Telisotuzumab vedotin: AbbVie
Datopotamab deruxtecan (Dato-DXd): AstraZeneca and Daiichi Sankyo

Non-Small Cell Lung Cancer Market Outlook

The dynamics of the Non-Small Cell Lung Cancer market is anticipated to change in the coming years owing to the expected launch of emerging therapies by key companies such as AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, and others during the forecast period 2020-2034.

Non-small Cell Lung Cancer Market

As more targetable mutations are identified and new targeted therapies are developed, both patients and oncologists will have an increasing number of treatment options. With the rapid pace of drug approvals, it is crucial to ensure that sufficient data supports the use of specific agents in appropriate treatment settings, including adjuvant, consolidation, first-line, and subsequent therapies.

Previously, molecular-based treatments were primarily used for advanced-stage Non-Small Cell Lung Cancer (NSCLC). However, recent research has demonstrated their effectiveness in early-stage and locally advanced disease. New studies are now investigating therapies targeting a broader range of oncogenes, aiming to overcome drug resistance and offer treatment options to patients who were previously ineligible for clinical trials on advanced-stage lung cancer. The emerging data from these ongoing trials are expected to shape future treatment guidelines and accelerate the adoption of personalized medicine. Consequently, the NSCLC treatment landscape is expected to continue evolving, leading to improved survival rates and a better quality of life for patients.

Non-Small Cell Lung Cancer Therapies and Key Companies
TransCon hGH: Ascendis Pharma
HyTropin (GX-H9): Genexine
Somatrogon: OPKO Health

Scope of the Non-Small Cell Lung Cancer Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Non-Small Cell Lung Cancer Companies: AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, and others
Key Non-Small Cell Lung Cancer Therapies: KEYTRUDA (pembrolizumab), TECENTRIQ (atezolizumab), Telisotuzumab vedotin, Datopotamab deruxtecan (Dato-DXd), and others
Non-Small Cell Lung Cancer Therapeutic Assessment: Non-Small Cell Lung Cancer current marketed and Non-Small Cell Lung Cancer emerging therapies
Non-Small Cell Lung Cancer Market Dynamics: Non-Small Cell Lung Cancer market drivers and Non-Small Cell Lung Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Non-Small Cell Lung Cancer Unmet Needs, KOL's views, Analyst's views, Non-Small Cell Lung Cancer Market Access and Reimbursement

ESMO Updates Covered by DelveInsight:

In December 2024, Shanghai Henlius Biotech presented findings from the serplulimab ASTRUM-004 trial at ESMO Asia 2024.
That same month, Daiichi Sankyo announced that a pooled analysis of the TROPION-Lung05 Phase II and TROPION-Lung01 Phase III trials demonstrated that Datopotamab deruxtecan produced a clinically meaningful tumor response in patients with previously treated advanced or metastatic EGFR-mutated NSCLC.
Additionally, in December 2024, PDC*line Pharma shared the primary clinical results from the final cohort of its Phase I/II trial with PDC*lung01 in an oral presentation at ESMO-IO 2024.
Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance
5. Non-Small Cell Lung Cancer Market Overview at a Glance
6. Non-Small Cell Lung Cancer Disease Background and Overview
7. Non-Small Cell Lung Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Non-Small Cell Lung Cancer
9. Non-Small Cell Lung Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Non-Small Cell Lung Cancer Emerging Therapies
12. Non-Small Cell Lung Cancer Market Outlook
13. Country-Wise Non-Small Cell Lung Cancer Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Non-Small Cell Lung Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Non-Small Cell Lung Cancer Market Outlook 2034.
Related Reports:

Non-Small Cell Lung Cancer Pipeline Insights, DelveInsight

"Non-Small Cell Lung Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Non-Small Cell Lung Cancer market. A detailed picture of the Non-Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Non-Small Cell Lung Cancer treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.